Research and Markets (http://www.researchandmarkets.com/research/539648/the_middle_eastern) has announced the addition of the "The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy Environment, Market Structure, Competitive Landscape, Growth Opportunities" report to their offering.
Recently, the countries of the Middle East have become increasingly important markets as a result of substantial investment in both the private and public sectors, introduction of mass health insurance and several moves to liberalize national economies. Egypt, Turkey, Saudi Arabia, Israel, Jordan, United Arab Emirates, Lebanon and Kuwait are the major countries of the Middle East with a total population of around 213m. Turkey, one of the key pharmerging markets of the world, is a strong proponent of liberal trade and investment policies. It has an open trading system, especially with countries in the EU, with which it forged a customs union agreement in 1996. Among the Gulf countries, Saudi Arabia is considered as the most attractive healthcare market in the Gulf which is mainly because of its rapidly growing population, enormous economic resources.
The Middle East pharmaceutical market is diverse, with a significant presence of leading global players alongside domestic pharmaceutical companies such as Ibrahim, Bilim and Deva. The market dynamics are further shaped by the presence of several leading suppliers of branded generics and APIs (active pharmaceutical ingredients) such as Teva, Hikma, Ibrahim, etc. Although, Middle East countries were a late entrant to the biotech sector, countries like Turkey, Saudi Arabia, UAE and Israel has made a dramatic progress in recent years, which was mainly due to several government initiatives. Moreover, several public-private partnerships also boosted the growth of pharmaceutical sector in the Middle East region.
Key findings